Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis

Zurück zum Zitat Authors/Task Force Members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619CrossRef Authors/Task Force Members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619CrossRef

Zurück zum Zitat Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505–1516CrossRefPubMed Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505–1516CrossRefPubMed

Zurück zum Zitat Mangiacapra F, Patti G, Barbato E, Peace AJ, Ricottini E, Vizzi V, Gatto L, D’Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G (2012) A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv 5:281–289CrossRefPubMed Mangiacapra F, Patti G, Barbato E, Peace AJ, Ricottini E, Vizzi V, Gatto L, D’Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G (2012) A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv 5:281–289CrossRefPubMed

Zurück zum Zitat Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36:1762–1771CrossRefPubMed Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36:1762–1771CrossRefPubMed

Zurück zum Zitat Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESCTFFUDOMI, Authors/Task FMC, Thygesen K, Alpert JS, White HD, Biomarker S, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman ECGS., Clemmensen BR, Johanson PM, Hod P, Imaging H, Underwood S, Bax R, Bonow JJ, Pinto JJ, Gibbons F, Classification RJ, Fox S, Atar KA, Newby D, Galvani LK, Hamm M, Intervention CW, Uretsky S, Steg BF, Wijns PG, Bassand W, Menasche JP, Ravkilde P, Trials J, Ohman RS, Antman EM, Wallentin EM, Armstrong LC, Simoons PW, Trials ML, Januzzi RS, Nieminen JL, Gheorghiade MS, Filippatos M, Trials G, Luepker RS, Fortmann RV, Rosamond SP, Levy WD, Wood D, Trials D, Smith RS, Hu SC, Lopez-Sendon D, Robertson JL, Weaver RM, Tendera D, Bove M, Parkhomenko AA, Vasilieva AN, Mendis EJ S, ESC Committee for Practice Guidelines CPG, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Document R, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR (2012) Third universal definition of myocardial infarction. J Am Coll Cardiol 60:1581–1598CrossRefPubMed Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESCTFFUDOMI, Authors/Task FMC, Thygesen K, Alpert JS, White HD, Biomarker S, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman ECGS., Clemmensen BR, Johanson PM, Hod P, Imaging H, Underwood S, Bax R, Bonow JJ, Pinto JJ, Gibbons F, Classification RJ, Fox S, Atar KA, Newby D, Galvani LK, Hamm M, Intervention CW, Uretsky S, Steg BF, Wijns PG, Bassand W, Menasche JP, Ravkilde P, Trials J, Ohman RS, Antman EM, Wallentin EM, Armstrong LC, Simoons PW, Trials ML, Januzzi RS, Nieminen JL, Gheorghiade MS, Filippatos M, Trials G, Luepker RS, Fortmann RV, Rosamond SP, Levy WD, Wood D, Trials D, Smith RS, Hu SC, Lopez-Sendon D, Robertson JL, Weaver RM, Tendera D, Bove M, Parkhomenko AA, Vasilieva AN, Mendis EJ S, ESC Committee for Practice Guidelines CPG, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Document R, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR (2012) Third universal definition of myocardial infarction. J Am Coll Cardiol 60:1581–1598CrossRefPubMed

Zurück zum Zitat Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic RC (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351CrossRefPubMed Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic RC (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351CrossRefPubMed

Zurück zum Zitat Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML (1988) Thrombolysis in Myocardial Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1–11CrossRefPubMed Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML (1988) Thrombolysis in Myocardial Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1–11CrossRefPubMed

Zurück zum Zitat Hamilos M, Muller O, Ntalianis A, Trana C, Bartunek J, Sarno G, Mangiacapra F, Dierickx K, Meeus P, Cuisset T, De Bruyne B, Wijns W, Barbato E (2011) Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. J Thromb Thrombolysis 32:64–71CrossRefPubMed Hamilos M, Muller O, Ntalianis A, Trana C, Bartunek J, Sarno G, Mangiacapra F, Dierickx K, Meeus P, Cuisset T, De Bruyne B, Wijns W, Barbato E (2011) Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. J Thromb Thrombolysis 32:64–71CrossRefPubMed

Zurück zum Zitat Mangiacapra F, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, D’Ambrosio A, Muller O, Barbato E, Di Sciascio G (2010) Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 106:619–623CrossRefPubMed Mangiacapra F, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, D’Ambrosio A, Muller O, Barbato E, Di Sciascio G (2010) Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 106:619–623CrossRefPubMed

Zurück zum Zitat Mangiacapra F, De Bruyne B, Muller O, Trana C, Ntalianis A, Bartunek J, Heyndrickx G, Di Sciascio G, Wijns W, Barbato E (2010) High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 3:35–40CrossRefPubMed Mangiacapra F, De Bruyne B, Muller O, Trana C, Ntalianis A, Bartunek J, Heyndrickx G, Di Sciascio G, Wijns W, Barbato E (2010) High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 3:35–40CrossRefPubMed

Zurück zum Zitat Mangiacapra F, Barbato E (2013) Clinical implications of platelet-vessel interaction. J Cardiovasc Transl Res 6:310–315CrossRefPubMed Mangiacapra F, Barbato E (2013) Clinical implications of platelet-vessel interaction. J Cardiovasc Transl Res 6:310–315CrossRefPubMed

Zurück zum Zitat Muller O, Hamilos M, Bartunek J, Ulrichts H, Mangiacapra F, Holz JB, Ntalianis A, Trana C, Dierickx K, Vercruysse K, De Bruyne B, Wijns W, Barbato E (2010) Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 105:333–338CrossRefPubMed Muller O, Hamilos M, Bartunek J, Ulrichts H, Mangiacapra F, Holz JB, Ntalianis A, Trana C, Dierickx K, Vercruysse K, De Bruyne B, Wijns W, Barbato E (2010) Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 105:333–338CrossRefPubMed

Zurück zum Zitat Mangiacapra F, Barbato E, Patti G, Gatto L, Vizzi V, Ricottini E, D’Ambrosio A, Wijns W, Di Sciascio G (2010) Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 3:318–323CrossRefPubMed Mangiacapra F, Barbato E, Patti G, Gatto L, Vizzi V, Ricottini E, D’Ambrosio A, Wijns W, Di Sciascio G (2010) Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 3:318–323CrossRefPubMed

Zurück zum Zitat Mangiacapra F, Bartunek J, Bijnens N, Peace AJ, Dierickx K, Bailleul E, Di Serafino L, Pyxaras SA, Fraeyman A, Meeus P, Rutten M, De Bruyne B, Wijns W, van de Vosse F, Barbato E (2012) Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. J Thromb Haemost 10:2452–2461CrossRefPubMed Mangiacapra F, Bartunek J, Bijnens N, Peace AJ, Dierickx K, Bailleul E, Di Serafino L, Pyxaras SA, Fraeyman A, Meeus P, Rutten M, De Bruyne B, Wijns W, van de Vosse F, Barbato E (2012) Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. J Thromb Haemost 10:2452–2461CrossRefPubMed

Zurück zum Zitat Mangiacapra F, Cavallari I, Ricottini E, Pellicano M, Barbato E, Di Sciascio G (2015) High platelet reactivity and periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a significant association beyond definitions. Int J Cardiol 190:124–125CrossRefPubMed Mangiacapra F, Cavallari I, Ricottini E, Pellicano M, Barbato E, Di Sciascio G (2015) High platelet reactivity and periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a significant association beyond definitions. Int J Cardiol 190:124–125CrossRefPubMed

Zurück zum Zitat Feldman DN, Kim L, Rene AG, Minutello RM, Bergman G, Wong SC (2011) Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 77:1020–1030CrossRefPubMed Feldman DN, Kim L, Rene AG, Minutello RM, Bergman G, Wong SC (2011) Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 77:1020–1030CrossRefPubMed

Zurück zum Zitat Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR, Rihal CS (2006) Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 48:1765–1770CrossRefPubMed Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR, Rihal CS (2006) Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 48:1765–1770CrossRefPubMed

Zurück zum Zitat Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monségu J, Sabouret P, O’Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, Vicaut E, Montalescot G, ARCTIC I (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109CrossRefPubMed Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monségu J, Sabouret P, O’Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, Vicaut E, Montalescot G, ARCTIC I (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109CrossRefPubMed

Zurück zum Zitat Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ, GRAVITAS I (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105CrossRefPubMed Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ, GRAVITAS I (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105CrossRefPubMed

Zurück zum Zitat Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 59:2159–2164CrossRefPubMed Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 59:2159–2164CrossRefPubMed

Zurück zum Zitat Mangiacapra F, Di Gioia G, Pellicano M, Di Serafino L, Bressi E, Peace AJ, Bartunek J, Wijns W, De Bruyne B, Barbato E (2016) Effects of prasugrel versus clopidogrel on coronary microvascular function in patients undergoing elective PCI. J Am Coll Cardiol 68:235–237CrossRefPubMed Mangiacapra F, Di Gioia G, Pellicano M, Di Serafino L, Bressi E, Peace AJ, Bartunek J, Wijns W, De Bruyne B, Barbato E (2016) Effects of prasugrel versus clopidogrel on coronary microvascular function in patients undergoing elective PCI. J Am Coll Cardiol 68:235–237CrossRefPubMed

Zurück zum Zitat Mangiacapra F, Panaioli E, Colaiori I, Ricottini E, Lauria Pantano A, Pozzilli P, Barbato E, Di Sciascio G (2016) Clopidogrel versus ticagrelor for antiplatelet maintenance in diabetic patients treated with percutaneous coronary intervention: results of the CLOTILDIA study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients). Circulation 134:835–837CrossRefPubMed Mangiacapra F, Panaioli E, Colaiori I, Ricottini E, Lauria Pantano A, Pozzilli P, Barbato E, Di Sciascio G (2016) Clopidogrel versus ticagrelor for antiplatelet maintenance in diabetic patients treated with percutaneous coronary intervention: results of the CLOTILDIA study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients). Circulation 134:835–837CrossRefPubMed

Zurück zum Zitat Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, PEGASUS-TIMI SCAI (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791–1800CrossRefPubMed Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, PEGASUS-TIMI SCAI (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791–1800CrossRefPubMed

Zurück zum Zitat Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M, PRECISE-DAPT SI (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389:1025–1034CrossRefPubMed Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M, PRECISE-DAPT SI (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389:1025–1034CrossRefPubMed

Zurück zum Zitat Pasea L, Chung SC, Pujades-Rodriguez M, Moayyeri A, Denaxas S, Fox KAA, Wallentin L, Pocock SJ, Timmis A, Banerjee A, Patel R, Hemingway H (2017) Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. Eur Heart J 38:1048–1055CrossRefPubMedPubMedCentral Pasea L, Chung SC, Pujades-Rodriguez M, Moayyeri A, Denaxas S, Fox KAA, Wallentin L, Pocock SJ, Timmis A, Banerjee A, Patel R, Hemingway H (2017) Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. Eur Heart J 38:1048–1055CrossRefPubMedPubMedCentral

Zurück zum Zitat Mangiacapra F, Ricottini E, Barbato E, Demartini C, Peace A, Patti G, Vizzi V, De Bruyne B, Wijns W, Di Sciascio G (2015) Incremental value of platelet reactivity over a risk score of clinical and procedural variables in predicting bleeding after percutaneous coronary intervention via the femoral approach: development and validation of a new bleeding risk score. Circ Cardiovasc Interv 8:e002106CrossRefPubMed Mangiacapra F, Ricottini E, Barbato E, Demartini C, Peace A, Patti G, Vizzi V, De Bruyne B, Wijns W, Di Sciascio G (2015) Incremental value of platelet reactivity over a risk score of clinical and procedural variables in predicting bleeding after percutaneous coronary intervention via the femoral approach: development and validation of a new bleeding risk score. Circ Cardiovasc Interv 8:e002106CrossRefPubMed